PDS Biotechnology Corporation
PDSBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The $80.4M market capitalization puts PDSB squarely in micro-cap range for its industry. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Market Cap
$80.4M
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-3.22
EPS (TTM)
$-0.64
EPS (Fwd)
$-0.34
ROE
-544.0%
ROA
-70.6%
Cash
$5.6M
Total Debt
$4.4M
Free CF
-$13.8M
52W Change
20.6%
Annual Financials
Cash vs Debt
Where PDSB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PDSB finished 10.84% above its 150-day moving average ($0.83) and 12.20% above its 200-day moving average ($0.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PDSB overbought or oversold?
At the October 20, 2026 close, PDSB's RSI(14) was 54.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $5.6M in cash and $4.4M in debt, PDSB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$13.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -544.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for PDS Biotechnology Corporation and its sector.